Episodes

  • The First CKM Syndrome Guidelines Are Here

    The First CKM Syndrome Guidelines Are Here
    Jul 17 2026

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "What to Know About the First CKM Syndrome Guidelines."

    Related Content:

    • What to Know About the First CKM Syndrome Guidelines
    Show More Show Less
    5 mins
  • The Testosterone Therapy Debate

    The Testosterone Therapy Debate
    Jul 10 2026

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?"

    Related Content:

    • Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?
    Show More Show Less
    6 mins
  • Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected

    Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected
    Jul 2 2026

    JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss "First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds."

    Related Content:

    • First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds
    Show More Show Less
    6 mins
  • PMOS is the New PCOS

    PMOS is the New PCOS
    Jun 26 2026

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "PCOS is Now PMOS—Will a New Name Translate to Improved Clinical Care?"

    Related Content:

    • PCOS Is Now PMOS—Will a New Name Translate to Improved Clinical Care?
    Show More Show Less
    6 mins
  • New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

    New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
    Jun 18 2026

    Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more.

    Related Content:

    • A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026
    Show More Show Less
    23 mins
  • Why Exercise Still Matters in the GLP-1 Drug Era

    Why Exercise Still Matters in the GLP-1 Drug Era
    Jun 18 2026

    JAMA Medical News Director Jennifer Abbasi and Staff Writer Samantha Anderer discuss "In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA."

    Related Content:

    • In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA
    Show More Show Less
    5 mins
  • The Search for a Fentanyl Vaccine

    The Search for a Fentanyl Vaccine
    Jun 12 2026

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Inside the Push for a Fentanyl Vaccine."

    Related Content:

    • Inside the Push for a Fentanyl Vaccine
    Show More Show Less
    6 mins
  • New Insights on HFpEF in Patients With Severe Obesity

    New Insights on HFpEF in Patients With Severe Obesity
    Jun 5 2026

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "HFpEF May Be a Different Disease in Patients With Severe Obesity."

    Related Content:

    • HFpEF May Be a Different Disease in Patients With Severe Obesity
    Show More Show Less
    5 mins